Innoviva Inc
INVA19.770USD
+0.260+1.33%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.48BMarket Cap
10.02P/E TTM
More Details of Innoviva Inc Company
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Innoviva Inc Info
Ticker SymbolINVA
Company nameInnoviva Inc
IPO dateOct 05, 2004
CEORaifeld (Pavel)
Number of employees127
Security typeOrdinary Share
Fiscal year-endOct 05
Address1350 Old Bayshore Highway
CityBURLINGAME
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94010
Phone16502389600
Websitehttps://www.inva.com/
Ticker SymbolINVA
IPO dateOct 05, 2004
CEORaifeld (Pavel)
Company Executives of Innoviva Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark A. Dipaolo, Esq.
Mr. Mark A. Dipaolo, Esq.
Chairman of the Board
Chairman of the Board
130.71K
+10.18%
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Lead Independent Director
Lead Independent Director
130.71K
+10.18%
Mr. Pavel Raifeld
Mr. Pavel Raifeld
Chief Executive Officer
Chief Executive Officer
124.90K
+763.58%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
44.10K
+11.98%
Mr. Stephen Basso
Mr. Stephen Basso
Chief Financial Officer
Chief Financial Officer
32.37K
+636.40%
Ms. Marianne Y. Zhen, CPA
Ms. Marianne Y. Zhen, CPA
Chief Accounting Officer
Chief Accounting Officer
25.73K
-3.71%
Mr. Jules A. Haimovitz
Mr. Jules A. Haimovitz
Independent Director
Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Director
Director
--
--
Mr. Derek A Small
Mr. Derek A Small
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark A. Dipaolo, Esq.
Mr. Mark A. Dipaolo, Esq.
Chairman of the Board
Chairman of the Board
130.71K
+10.18%
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Lead Independent Director
Lead Independent Director
130.71K
+10.18%
Mr. Pavel Raifeld
Mr. Pavel Raifeld
Chief Executive Officer
Chief Executive Officer
124.90K
+763.58%
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
44.10K
+11.98%
Mr. Stephen Basso
Mr. Stephen Basso
Chief Financial Officer
Chief Financial Officer
32.37K
+636.40%
Ms. Marianne Y. Zhen, CPA
Ms. Marianne Y. Zhen, CPA
Chief Accounting Officer
Chief Accounting Officer
25.73K
-3.71%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
100.28M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.15%
The Vanguard Group, Inc.
9.47%
Renaissance Technologies LLC
6.13%
Dimensional Fund Advisors, L.P.
5.79%
Sarissa Capital Management, L.P.
3.77%
Other
63.68%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.15%
The Vanguard Group, Inc.
9.47%
Renaissance Technologies LLC
6.13%
Dimensional Fund Advisors, L.P.
5.79%
Sarissa Capital Management, L.P.
3.77%
Other
63.68%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.93%
Investment Advisor/Hedge Fund
33.77%
Hedge Fund
18.89%
Research Firm
5.17%
Bank and Trust
3.30%
Pension Fund
1.33%
Individual Investor
1.07%
Sovereign Wealth Fund
0.15%
Family Office
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
506
75.62M
101.14%
-2.32M
2025Q2
497
69.38M
110.09%
-7.80M
2025Q1
503
69.52M
110.75%
-9.29M
2024Q4
492
73.18M
116.75%
-6.44M
2024Q3
487
75.41M
120.47%
-5.51M
2024Q2
492
75.89M
121.41%
-5.03M
2024Q1
502
75.85M
119.80%
-4.18M
2023Q4
494
74.97M
116.88%
-1.82M
2023Q3
486
71.34M
109.51%
-8.23M
2023Q2
482
72.90M
111.23%
-6.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
8.09M
12.84%
-148.59K
-1.80%
Jun 30, 2025
The Vanguard Group, Inc.
7.16M
11.36%
+879.54K
+14.00%
Jun 30, 2025
Renaissance Technologies LLC
4.76M
7.55%
--
--
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.29M
6.81%
-365.40K
-7.84%
Jun 30, 2025
Sarissa Capital Management, L.P.
2.82M
4.47%
--
--
Jun 30, 2025
State Street Investment Management (US)
2.46M
3.9%
+93.69K
+3.96%
Jun 30, 2025
Putnam Investment Management, L.L.C.
2.75M
4.37%
-1.14M
-29.37%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
1.71M
2.71%
+786.41K
+85.29%
Jun 30, 2025
American Century Investment Management, Inc.
2.07M
3.28%
+391.06K
+23.34%
Jun 30, 2025
Bank of Nova Scotia
3.59M
5.69%
-4.06M
-53.09%
Aug 29, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.33%
State Street SPDR S&P Pharmaceuticals ETF
2.27%
ETC 6 Meridian Small Cap Equity ETF
2.06%
Vanguard US Minimum Volatility ETF
1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.06%
Invesco S&P SmallCap Low Volatility ETF
0.91%
Acquirers Small and Micro Deep Value ETF
0.9%
Invesco S&P SmallCap Health Care ETF
0.67%
VictoryShares US Small Mid Cap Value Momentum ETF
0.59%
View more
Invesco Pharmaceuticals ETF
Proportion2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.33%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.27%
ETC 6 Meridian Small Cap Equity ETF
Proportion2.06%
Vanguard US Minimum Volatility ETF
Proportion1.64%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.06%
Invesco S&P SmallCap Low Volatility ETF
Proportion0.91%
Acquirers Small and Micro Deep Value ETF
Proportion0.9%
Invesco S&P SmallCap Health Care ETF
Proportion0.67%
VictoryShares US Small Mid Cap Value Momentum ETF
Proportion0.59%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Innoviva Inc?
The top five shareholders of Innoviva Inc are:
BlackRock Institutional Trust Company, N.A. holds 8.09M shares, accounting for 12.84% of the total shares.
The Vanguard Group, Inc. holds 7.16M shares, accounting for 11.36% of the total shares.
Renaissance Technologies LLC holds 4.76M shares, accounting for 7.55% of the total shares.
Dimensional Fund Advisors, L.P. holds 4.29M shares, accounting for 6.81% of the total shares.
Sarissa Capital Management, L.P. holds 2.82M shares, accounting for 4.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.09M shares, accounting for 12.84% of the total shares.
The Vanguard Group, Inc. holds 7.16M shares, accounting for 11.36% of the total shares.
Renaissance Technologies LLC holds 4.76M shares, accounting for 7.55% of the total shares.
Dimensional Fund Advisors, L.P. holds 4.29M shares, accounting for 6.81% of the total shares.
Sarissa Capital Management, L.P. holds 2.82M shares, accounting for 4.47% of the total shares.
What are the top three shareholder types of Innoviva Inc?
The top three shareholder types of Innoviva Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Renaissance Technologies LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Renaissance Technologies LLC
How many institutions hold shares of Innoviva Inc (INVA)?
As of 2025Q3, 506 institutions hold shares of Innoviva Inc, with a combined market value of approximately 75.62M, accounting for 101.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.95%.
What is the biggest source of revenue for Innoviva Inc?
In FY2025Q2, the -- business generated the highest revenue for Innoviva Inc, amounting to -- and accounting for --% of total revenue.
